SG11202012819YA - Tricyclic compounds - Google Patents

Tricyclic compounds

Info

Publication number
SG11202012819YA
SG11202012819YA SG11202012819YA SG11202012819YA SG11202012819YA SG 11202012819Y A SG11202012819Y A SG 11202012819YA SG 11202012819Y A SG11202012819Y A SG 11202012819YA SG 11202012819Y A SG11202012819Y A SG 11202012819YA SG 11202012819Y A SG11202012819Y A SG 11202012819YA
Authority
SG
Singapore
Prior art keywords
tricyclic compounds
tricyclic
compounds
Prior art date
Application number
SG11202012819YA
Other languages
English (en)
Inventor
Haiquan Fang
Mingming Chen
Guiqun Yang
Yuelei Du
Yanping Wang
Tong Wu
Qinglong Li
Lei Zhang
Shaojing Hu
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of SG11202012819YA publication Critical patent/SG11202012819YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11202012819YA 2018-06-25 2019-04-26 Tricyclic compounds SG11202012819YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018092542 2018-06-25
PCT/CN2019/084601 WO2020001152A1 (en) 2018-06-25 2019-04-26 Tricyclic compounds

Publications (1)

Publication Number Publication Date
SG11202012819YA true SG11202012819YA (en) 2021-01-28

Family

ID=68986044

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012819YA SG11202012819YA (en) 2018-06-25 2019-04-26 Tricyclic compounds

Country Status (15)

Country Link
US (2) US20210179617A1 (ja)
EP (1) EP3814352A4 (ja)
JP (1) JP7168245B2 (ja)
KR (1) KR102600391B1 (ja)
CN (2) CN112513041B (ja)
AU (2) AU2019295983B2 (ja)
BR (1) BR112020026337A2 (ja)
CA (1) CA3104927C (ja)
EA (1) EA202190103A1 (ja)
MX (1) MX2020014111A (ja)
PH (1) PH12020552210A1 (ja)
SG (1) SG11202012819YA (ja)
TW (1) TWI705965B (ja)
WO (1) WO2020001152A1 (ja)
ZA (1) ZA202100237B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020026337A2 (pt) * 2018-06-25 2021-03-30 Jacobio Pharmaceuticals Co., Ltd. Compostos tricíclicos
EP4281451A1 (en) * 2021-01-22 2023-11-29 Jingrui Biopharma Co., Ltd. Tricyclic compounds as anticancer agents
WO2024099441A1 (en) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Bromodomain and extra-terminal (bet) protein degrader

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103848818B (zh) * 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
CN105377851B (zh) * 2013-03-11 2018-07-20 密执安州立大学董事会 Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
PE20160844A1 (es) * 2013-12-24 2016-09-03 Bristol Myers Squibb Co Compuestos triciclicos como agentes anticancerigenos
EP3294736B1 (en) * 2015-05-11 2020-07-22 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) * 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10174024B2 (en) * 2015-05-12 2019-01-08 Bristol-Myers Squibb Company 5H-pyrido[3,2-B]indole compounds as anticancer agents
EP3406612B1 (en) * 2016-01-20 2021-07-21 Ningbo Wenda Pharma Technology Ltd. Carboline derivative serving as bromodomain inhibitor
EP3412669A4 (en) 2016-02-05 2019-09-04 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2019080941A1 (en) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. NEW TRICYCLIC COMPOUNDS
BR112020026337A2 (pt) * 2018-06-25 2021-03-30 Jacobio Pharmaceuticals Co., Ltd. Compostos tricíclicos
CN113544129A (zh) * 2019-04-04 2021-10-22 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用

Also Published As

Publication number Publication date
CN112513041B (zh) 2022-05-10
ZA202100237B (en) 2022-10-26
CN112513041A (zh) 2021-03-16
AU2019295983A1 (en) 2021-02-11
CA3104927C (en) 2023-09-12
JP2021530455A (ja) 2021-11-11
US20220119390A1 (en) 2022-04-21
KR102600391B1 (ko) 2023-11-10
US20210179617A1 (en) 2021-06-17
AU2019295983B2 (en) 2021-09-30
WO2020001152A1 (en) 2020-01-02
CA3104927A1 (en) 2020-01-02
JP7168245B2 (ja) 2022-11-09
AU2021290208A1 (en) 2022-01-20
EA202190103A1 (ru) 2021-03-29
BR112020026337A2 (pt) 2021-03-30
MX2020014111A (es) 2021-06-15
CN115109061A (zh) 2022-09-27
EP3814352A4 (en) 2022-03-30
US11466005B2 (en) 2022-10-11
AU2021290208B2 (en) 2023-09-21
TWI705965B (zh) 2020-10-01
KR20210045981A (ko) 2021-04-27
TW202017928A (zh) 2020-05-16
PH12020552210A1 (en) 2021-06-28
EP3814352A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
ZA202207722B (en) Substituted tricyclic compounds
ZA202206253B (en) Substituted tricyclic compounds
PL3810602T3 (pl) Związki
GB201805174D0 (en) Compounds
GB202108469D0 (en) Compounds
GB201807924D0 (en) Compounds
GB201810581D0 (en) Compounds
ZA202100237B (en) Tricyclic compounds
IL282366A (en) Tricyclic pesticidal compounds
GB201814151D0 (en) Compounds
GB201808093D0 (en) Compounds
FI3810633T3 (fi) Yhdisteitä
GB201809102D0 (en) Compounds
GB201817083D0 (en) Compounds
GB201810071D0 (en) Compounds
IL287813A (en) tricyclic compounds
GB201803340D0 (en) Compounds
GB201814167D0 (en) Compounds
GB201812382D0 (en) Compounds
GB201801130D0 (en) Compounds
GB201801128D0 (en) Compounds
HUP1800332A1 (hu) Triciklusos vegyületek II
HUP1700522A1 (hu) Triciklusos vegyületek
GB201817291D0 (en) Compounds
GB201817303D0 (en) Compounds